At Verseau, we are advancing a new class of cancer immunotherapies to stimulate the conversion of immuno-suppressive and pro-tumorigenic M2 macrophages into pro-inflammatory M1 macrophages. This transformation, called macrophage repolarization, induces a coordinated immune response to fight cancer.
Verseau’s proprietary human-based discovery engine has identified and validated over 20 targets for regulating macrophage biology.
Our two lead programs targeting PSGL-1 and VSIG4 are rapidly advancing toward the clinic.